Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening

Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Laios, Alexandros, Mohamed, Bashir M., Kelly, Lynne, Flavin, Richard, Finn, Stephen, McEvoy, Lynda, Gallagher, Michael, Martin, Cara, Sheils, Orla, Ring, Martina, Davies, Anthony, Lawson, Margaret, Gleeson, Noreen, D’Arcy, Tom, d’Adhemar, Charles, Norris, Lucy, Langhe, Ream, Saadeh, Feras Abu, O’Leary, John J., O’Toole, Sharon A.
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3565367/
https://ncbi.nlm.nih.gov/pubmed/23340649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms14012085
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars